MedTrace Logo

Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C

NCT00527540 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-01-21

No results posted yet for this study

Summary

Pegylation of interferon prolongs the medication half-life which has resulted in Pegylated Interferon (PEG-IFN) as the new modality for treatment of chronic hepatitis C. We current this clinical trial to assess the efficacy and safety of domestic PEG-IFN alpha-2a (Pegaferon®) in the patients with chronic hepatitis C.

Conditions

  • Hepatitis C

Interventions

DRUG

Pegylated Interferon alpha 2a + Ribavirin

Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day

Sponsors & Collaborators

  • Kermanshah University of Medical Sciences

    collaborator OTHER

  • Tehran Hepatitis Center

    lead OTHER

Principal Investigators

  • Seyed M Alavian, Prof. · Tehran Hepatitis Center

  • Behzad Hajarizadeh, MD · Tehran Hepatitis Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2008-06-30
Completion
2008-12-31

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00527540 on ClinicalTrials.gov